Compliance
How to Use Ignatia amara
(Image: Steven Edward/Flickr) By Todd A. Hoover, MD, DHt The homeopathic medicine Ignatia amara is derived from the St. Ignatius Bean (from the Strychnos ignatii plant). The tree is in the Loganiaceae family, and considered native to the Philippines and was naturalized into parts of China. The plant was first readm more…
Read MoreThe French Pharmacopeia
By Eric Foxman, R.Ph., AAHP Secretary A quick look at its structure and contents as well as two key considerations for potential adulteration and misbranding in the U.S. market. Structure The French Pharmacopeia (FP) is a publication of the National Agency for the Safety of Medicines and Health Products (ANSM), readm more…
Read MoreHow to Use Gelsemium sempervirens
By Todd A. Hoover, MD, DHt Gelsemium sempervirens is a plant substance, commonly known as yellow jasmine, native to tropical and subtropical Americas. The traditional herbal use was for a number of neurological and dermatological problems including measles, ear pain, dysmenorrhea, headaches, muscle pain, and anxiety. All parts of the readm more…
Read MoreProcess Validation of Homeopathic Medicines
By Pejman Parhami, Senior Director, Quality Systems, Hyland’s, Inc. FDA issued many warning letters regarding process validation in 2017 and 2018. were more prominent. Of the warning letters analyzed, about 40% included observations related to process validation. Since 2017, about 30 facilities were found to be noncompliant with respect readm more…
Read MoreA Brief Regulatory History of Process Validation
By Mark Land, AAHP President Finished product testing is probabilistic and not dispositive of process control; that is why we need process validation. While preparing this article I came across several histories of process validation. One that caught my attention was a book chapter written by Bernard Loftus, formerly readm more…
Read MoreThe Case for Process Validation
By Mark Land, AAHP President The Homeopathic Pharmacopoeia of the United States says: “Dosage Forms – These, like all other conditions of homeopathic production should be governed by simplicity and usefulness to the physician and patient.”1 This is a good place to start a discussion about process validation for readm more…
Read MoreReview Notice: Comparison of Machines to Potentize Homeopathic Drug Products
By Eric Foxman, AAHP Secretary In April, AAHP posted an article about the different machines used to potentize homepathic medicines. Coincidentally, Homeopathy recently published a paper comparing machines that potentize homeopathic drug products. AAHP will not reprint this paper, A Review of Machines and Devices to Potentize Homeopathic Medicines, due readm more…
Read MoreThe British Homœopathic Pharmacopœia
By Eric Foxman, AAHP Secretary A quick look at its history, purpose, and contents, as well as the potential for adulteration and misbranding violations in the U.S. market. readm more…
Read MoreHealth Care Product Recalls
By Mark Land, AAHP President July 1, 2018 Product recalls are an important tool for manufacturers and the Food and Drug Administration (FDA) to minimize exposure to potentially harmful or ineffective products. Drug product recalls are voluntary — that is to say FDA does not have legal authority to recall readm more…
Read MoreLatest Updates to the HPUS
By Eric L. Foxman, Senior Scientist, HPCUS, AAHP secretary June 4, 2018 Of all the changes implemented by the Homeopathic Pharmacopoeia Convention of the United States (HPCUS) in the past year, perhaps the most important is a new function: you can sign up to now receive email notifications of updates readm more…
Read More